Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Kabir Nath, Sonic AI
Home
/
Discover
/
Kabir Nath
K
Kabir Nath
Person
13
Mentions
Episodes
13
Claims
Claims
By Source
Timeline
All
(13)
Business
(2)
Healthcare
(10)
Government
(1)
Tech
(0)
Energy
(0)
Science
(0)
Geopolitics
(0)
Compass Pathways believes it is significantly ahead of competitors and could be the first company to market with an FDA-approved psilocybin therapy.
Expert perspective
Kabir Nath
Apr 21
Treatment-resistant depression affects approximately 4 million people in the United States.
Expert perspective
Kabir Nath
Apr 21
Compass Pathways is confident it can secure insurance coverage for COMP360 from both commercial and government payers after receiving FDA approval.
Expert perspective
Kabir Nath
Apr 21
In a second late-stage study by Compass Pathways, 40% of patients experienced a meaningful reduction in depression symptoms.
Expert perspective
Kabir Nath
Apr 21
Compass Pathways is also studying its synthetic psilocybin, COMP360, for the treatment of Post-Traumatic Stress Disorder (PTSD).
Expert perspective
Kabir Nath
Apr 21
Compass Pathways is developing a synthetic, proprietary form of psilocybin, named COMP360, for the treatment of treatment-resistant depression (TRD).
Expert perspective
Kabir Nath
Apr 21
Compass Pathways plans to potentially complete its regulatory submission to the FDA for COMP360 later this year.
Expert perspective
Kabir Nath
Apr 21
Kabir Nath is confident that Compass Pathways will have a more successful regulatory outcome with the FDA than Lycos Therapeutics due to superior data and trial design.
Expert perspective
Kabir Nath
Apr 21
Compass Pathways' clinical data indicates that the therapeutic effects from one or two administrations of its psilocybin treatment can last for up to six months.
Expert perspective
Kabir Nath
Apr 21
Compass Pathways' clinical trial protocol provides its psilocybin medicine with psychological support, but does not include formal psychotherapy as part of the treatment.
Expert perspective
Kabir Nath
Apr 21
A recent executive order is intended to accelerate the DEA's process for reclassifying certain psychedelic medicines following potential FDA approval.
Expert perspective
Kabir Nath
Apr 21
The two late-stage clinical studies for COMP360 by Compass Pathways included a total of over 800 patients.
Expert perspective
Kabir Nath
Apr 21
In one of Compass Pathways' late-stage studies, 25% of patients experienced a meaningful reduction in depression symptoms from a single administration of COMP360.
Expert perspective
Kabir Nath
Apr 21
Sign up free to see the full entity analysis
Get started free
Back to Entities
Entity Detail